Yeah, the good and the bad of having work done by an independent researcher, good being independent, bad being they don't want all the data given in press releases until they publish. We do know the FDA approved the phase 2 trial based on this data. So we know it must be good data, we just don't know how good compared to others, depending on how 'effectively' it inhibited.

Quote:

---

Daniel Lindner, M.D., Ph.D. of the Cleveland Clinic, who conducted the studies, stated: “Our results showed that leronlimab effectively inhibited fatty liver development, the hallmark of early stages of NASH.”

---